Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8944830 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL9349967 | 0.82 | TDP1 (0.55) | SMN1; SMN2TDP1L3MBTL1HPGDHDAC8 | |
| SCHEMBL12362807 | 0.82 | CHRM2 (0.56) | TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL30881314 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL7104225 | 0.80 | POLB (0.46) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL24060310 | 0.79 | TDP1 (0.54) | TDP1L3MBTL1CYP1A2CYP2C19 | |
| SCHEMBL10655528 | 0.79 | CHRM2 (0.53) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL8837648 | 0.79 | MEN1 (0.45) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL6389018 | 0.78 | TDP1 (0.47) | SMN1; SMN2TDP1L3MBTL1MAPTRAB9A | |
| SCHEMBL13320344 | 0.78 | CHRM2 (0.51) | CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| US-20130295040-A1 | POLYMER | WARWICK EFFECT POLYMERS LTD (US) | 2013-11-07 | — | — | US | disclosed |
| US-8436104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20080300348-A1 | Polymer | WARWICK EFFECT POLYMERS LIMITED | 2008-12-04 | — | — | US | disclosed |
| EP-1784430-A1 | LIVING RADICAL POLYMERIZATION INITIATOR COMPRISING A FUNCTIONAL GROUP CAPABLE OF REACTING WITH POLYEPTIDES OR THE LIKE, COMB POLYMER OBTAINED THEREWITH , POLYPEPTIDE CONJUGATES AND DRUGS OBTAINED THEREFROM. | Warwick Effect Polymers Limited (GB) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006003352-A1 | LIVING RADICAL POLYMERIZATION INITIATOR COMPRISING A FUNCTIONAL GROUP CAPABLE OF REACTING WITH POLYEPTIDES OR THE LIKE, COMB POLYMER OBTAINED THEREWITH, POLYPEPTIDE CONJUGATES AND DRUGS OBTAINED THEREFROM | WARWICK EFFECT POLYMERS LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130295040-A1 | POLYMER | PCNA, PARG, COASY | MMP2 2755/4885MMP9 3957/4885SMN1; SMN2 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.